The microneedles deliver medication directly between the choroid and sclera to treat retinal disease and are hoped to be more effective than eye drops and less invasive than hypodermic needles or surgery. Trials of its product CLS1001 are expected to begin this quarter.
More Articles on Ophthalmology:
Dr. Yingbin Fu of Moran Eye Center Receives National Eye Institute Award
Toyos Clinic in Memphis Merges With Ophthalmology Management of Nashville
Coastal Bend Eye Center in Texas Hires New Optician
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
